Project Grant R01AI182322
Award Date
7/1/24
Completion Date
5/31/29
Dollars Obligated
$727K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Atlanta, GA 30332, USA
Similar Awards
This $238,500 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The objective is to develop and validate a novel electrochemical lateral flow assay (ELFA) that can accurately diagnose active tuberculosis (TB) from a single drop of blood or urine, addressing limitations of current sputum-based TB diagnostics. The specific aims are to: 1) Determine the operating characteristics of...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products/services being delivered include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect live Mycobacterium tuberculosis (MTB) and...
This $737,342 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development and validation of advanced imaging technologies to enable more sensitive detection of Mycobacterium tuberculosis (MTB), the causative agent of tuberculosis (TB). The project aims to: 1) develop new imaging methods capable of detecting single bacteria in vitro and in vivo, 2) improve imaging to...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,413,007.00 to the University of Washington to develop and evaluate an ultra-sensitive CRISPR-based diagnostic tool called CRISPR-TB. The goal is to enable early and accurate detection of tuberculosis (TB) in children under 5 years old, a population that is disproportionately impacted by TB but least likely...
This $3,413,412 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research into developing a novel tuberculosis (TB) vaccine. The Texas Biomedical Research Institute, doing business as Southwest Foundation For Biomedical Research, is the primary grant recipient and will use cutting-edge techniques like single-cell RNA sequencing and PET/CT imaging to study the immune...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $718,758 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Texas Biomedical Research Institute to investigate the use of an IL-21-IgFc fusion protein in combination with antiretroviral therapy (ART) and three-month isoniazid and rifapentine (3HP) treatment to mitigate immune dysfunction in tuberculosis (TB) and simian immunodeficiency virus (SIV) co-infection. The goal is to...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $209,750.00 to Emory University to conduct research aimed at leveraging antibody-based biomarkers to prevent and detect tuberculosis (TB) in children affected by HIV. The key objectives are to: 1) Define antibody features associated with protection from Mycobacterium tuberculosis (MTB) infection among HIV-exposed...
This $820,246 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify and characterize the specific proteins secreted by the ESX5 transport system in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). The research aims to determine the roles of these secreted proteins in TB pathogenesis and immunity, as well as investigate why an ESX5...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000.00 to Salus Discovery LLC to develop a next-generation urine-based lateral flow assay (LFA) for tuberculosis (TB) diagnosis in point-of-care settings. The project, titled "FLOW DIRECT: NEXT GENERATION URINE LFA FOR TB DIAGNOSIS IN POINT-OF-CARE SETTINGS", aims to address the critical gap in access to...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $743,698 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Trustees of Boston University to characterize the burden, severity, and phenotypic presentation of post-tuberculosis lung disease (PTLD) and its association with interleukin-6 (IL-6) signaling pathways in tuberculosis (TB) patients with and without HIV. The project will leverage an ongoing TB research consortium in India to...